CliffBio
biologic

Orencia

abatacept

Loss of exclusivityJune 2028projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →See this company's full patent-cliff portfolio

Drug detail

Brand nameOrencia
Active ingredientabatacept
Strength125MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2016
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Orencia patent cliff — loss of exclusivity June 2028 | CliffBio